Eli Lilly and Company

Samantha Grace Lyons Keyser

John Lee

Hongchang Qu

Lili Guo

Jorge Alsina-Fernandez

Andrea Renee Geiser

William Christopher Roell

Daniel Anthony Briere

Milata Mary Abraham

The present disclosure relates to the field of medicine. More particularly, the disclosure is in the field of treatment of diabetes, obesity and/or chronic weight management, dyslipidemia and/or NASH. The disclosure relates to compounds that agonize the amylin receptor and can lower food intake, body weight, glucose and/or triglycerides, so can be used to treat diabetes, obesity, and/or dyslipidemia. The present disclosure also includes pharmaceutical compositions containing such compounds and therapeutic uses of such compounds and compositions.

Long acting amylin receptor agonists and uses thereof

The present invention relates to compounds having activity at the human glucose-dependent insulinotropic polypeptide (GIP) receptor. The present invention also relates to compounds having an extended duration of action at the GIP receptor. Such compounds may be useful in the treatment of diabetes, including type 2 diabetes mellitus ('T2DM'). Also, the compounds may be useful in the treatment of obesity.

GIPR-agonist compounds

Growing community of inventors

Carmel, IN, United States of America

Samantha Grace Lyons Keyser